SCHEMBL23539751

SCHEMBL23539751

COC(=O)c1cc(C(F)(F)F)c(-c2ccc(F)cc2F)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 10/20 0.56
ALPL P05186 1/20 0.43
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GLA P06280 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
ATM Q13315 1/20 0.40
PDK2 Q15119 1/20 0.40
ABL1 P00519 1/20 0.40
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
NOTUM Q6P988 1/20 0.37
IKBKB O14920 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29476378 1.00 CFTR (0.56) CFTRALPLKDM4EALDH1A1GAA
SCHEMBL24525540 0.85 CFTR (0.48) CFTRKDM4EALDH1A1GAAMAPT
SCHEMBL29654327 0.85 CFTR (0.48) CFTRKDM4EALDH1A1GAAMAPT
SCHEMBL29476183 0.85 CFTR (0.60) CFTRKDM4EALDH1A1GAAMAPT
SCHEMBL23540424 0.85 CFTR (0.60) CFTRKDM4EALDH1A1GAAMAPT
SCHEMBL25326637 0.84 CFTR (0.52) CFTRKDM4EALDH1A1GAAMAPT
SCHEMBL23556347 0.83 ALPL (0.46) CFTRALPLKDM4EALDH1A1GAA
SCHEMBL23539893 0.82 ABL1 (0.48) CFTRALPLKDM4EALDH1A1GAA
SCHEMBL23540616 0.82 CFTR (0.56) CFTRALPLKDM4EALDH1A1GAA
SCHEMBL29476388 0.82 ABL1 (0.48) CFTRALPLKDM4EALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162893-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2024-12-10 US disclosed
US-11845761-B2 Tricyclic pyridones and pyrimidones ERASCA, INC. (US) 2023-12-19 US disclosed
EP-4217071-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES Erasca, Inc. (US) 2023-08-02 EP disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 US disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 US disclosed
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-06-29 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-05-25 US disclosed
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2023-04-06 US disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 WO disclosed
WO-2022133345-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2022-06-23 WO disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 US disclosed
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. 2022-04-21 US disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 WO disclosed
WO-2021127404-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES ERASCA, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203063-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES TYMS, TYMP, DHFR CFTR 2318/4885ALPL 4740/4885KDM4E 3587/4885
US-20220119409-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES DHFR, TYMS, TYMP CFTR 1960/4885ALPL 4714/4885KDM4E 3415/4885
US-20230107642-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS CFTR 1205/4885ALPL 4739/4885KDM4E 2592/4885
US-11845761-B2 Tricyclic pyridones and pyrimidones KRAS, NRAS, HRAS CFTR 1205/4885ALPL 4739/4885KDM4E 2592/4885
US-12162893-B2 Tricyclic pyridones and pyrimidones DHFR, TYMS, TYMP CFTR 1960/4885ALPL 4714/4885KDM4E 3415/4885
US-20230159563-A1 TRICYCLIC PYRIDONES AND PYRIMIDONES KRAS, NRAS, HRAS CFTR 1205/4885ALPL 4739/4885KDM4E 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.